Pilot study of the incretin effect on the immunological phenotype in healthy subjects and subjects with type 1 diabetes: Step 4 of the Austrian Diabetes Prevention Programme (ADPP-004).

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-006300-12-AT

Enrollment

Registered

2012-01-24

Start date

2012-02-23

Completion date

Unknown

Last updated

2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteers

Interventions

Trade Name: Victoza Product Name: Victoza Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: LIRAGLUTIDE CAS Number: 204656-20-2 Other descriptive name: GLP-1 Analogon

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 32 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Austria

Contacts

Public ContactKlin.Abt. f. Endokrin. u. Stoffw.

Medizinische Universität Graz

gerlies.bock@medunigraz.at004331638512383

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026